Research Library › Peptide Fragments
Follistatin is a naturally occurring glycoprotein, encoded by the FST gene, that binds activin and related members of the TGF-beta protein family. It was first isolated from porcine ovarian follicular fluid and reported in 1987 by Nicholas Ueno, Shunichi Shimasaki, Roger Guillemin and colleagues at the Salk Institute. As of October 2026 no follistatin product is approved by the FDA or the EMA; gene-transfer forms have reached only early-phase clinical studies.
Key facts
| Type | Natural single-chain glycoprotein (not a short peptide) |
|---|---|
| Gene | FST, human chromosome 5q11.2, six exons |
| Main isoforms | FS315 (from the 344-amino-acid precursor FS344) and FS288 (from the 317-amino-acid precursor) |
| First described | 1987, as an FSH-suppressing protein from porcine follicular fluid |
| Developed by | Discovered by Ueno, Ling, Ying, Esch, Shimasaki and Guillemin, Salk Institute |
| Designed target | Binds activin and other TGF-beta family ligands, including myostatin (GDF-8) |
| Regulatory status (Oct 2026) | Not FDA-approved or EMA-authorized in any form; listed by WADA under S4 as a myostatin-binding protein |
Who discovered it
Follistatin was discovered during the search for gonadal hormones that regulate the pituitary. In 1987 a team at the Salk Institute in La Jolla led by Nobel laureate Roger Guillemin, with Nicholas Ueno, Nicholas Ling, Shao-Yao Ying, Fred Esch and Shunichi Shimasaki, purified a single-chain protein from porcine ovarian follicular fluid that suppressed release of follicle-stimulating hormone (FSH) from pituitary cells in culture. They named it follistatin [1].
In 1988 Shimasaki and colleagues reported the structure of the human follistatin precursor and its gene [2]. Two years later a Japanese group showed that an activin-binding protein from rat ovary was identical to follistatin, which explained how it acts on FSH: by binding activin rather than through its own receptor [3].
Structure and isoforms
Follistatin is a glycoprotein of a few hundred amino acids, far larger than the short peptides usually discussed in research catalogs. The FST gene sits on human chromosome 5q11.2 and has six exons [2, 4]. Alternative splicing at the last exon produces two precursor proteins of 344 and 317 amino acids. After removal of a 29-residue signal peptide they give the two main mature forms, FS315 and FS288 [4].
FS315 carries an acidic C-terminal tail, which blocks binding to heparan sulfate on cell surfaces; FS288 lacks that tail and binds cell-surface proteoglycans more readily [4]. In research literature the name follistatin-344 (FS344) refers to the longer precursor form, and it is the version encoded in the gene-transfer vectors described below [5].
A 2005 crystal structure showed two follistatin molecules wrapping around one activin dimer, covering the sites activin uses to engage its receptors [6]. Follistatin also binds other members of the same protein family, including myostatin (GDF-8), which is why WADA lists it among myostatin-binding proteins [8].
Research history
Most follistatin research is basic biology on reproduction, development and TGF-beta signaling. A smaller body of work has studied delivering the FS344 gene with adeno-associated virus (AAV) vectors. At Nationwide Children’s Hospital in Columbus, Ohio, Jerry Mendell’s group ran an early-phase gene-transfer study of rAAV1.CMV.huFollistatin344 in a research program on Becker muscular dystrophy and sporadic inclusion body myositis; it is registered as NCT01519349 and listed as completed [5, 7].
- 1987: Follistatin isolated from porcine follicular fluid at the Salk Institute [1]
- 1988: Human follistatin precursor and gene structure reported [2]
- 1990: Follistatin identified as an activin-binding protein [3]
- 2005: Crystal structure of the follistatin–activin complex published [6]
- 2012–2017: Phase 1 FS344 gene-transfer study at Nationwide Children’s Hospital [5, 7]
Regulatory status as of October 2026
No follistatin protein, peptide or gene therapy is approved by the US Food and Drug Administration or authorized by the European Medicines Agency. Clinical work has been limited to early-phase, investigator-led gene-transfer studies, and the Becker/inclusion body myositis study is listed with an inactive development status [7].
On the 2026 WADA Prohibited List, follistatin is named under section S4 (hormone and metabolic modulators) as an example of a myostatin-binding protein [8].
About this reference page
Kalibra Labs does not currently supply Follistatin. This page is published as a neutral scientific and regulatory reference. Browse the Peptide Fragments guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Who discovered follistatin?
Follistatin was isolated from porcine ovarian follicular fluid and reported in 1987 by Ueno, Ling, Ying, Esch, Shimasaki and Guillemin at the Salk Institute [1].
What is follistatin-344?
FS344 is the 344-amino-acid precursor form of follistatin produced by one splice variant of the FST gene. After its signal peptide is removed it becomes the mature FS315 protein [4, 5].
Is follistatin a peptide?
Not in the usual sense. It is a full-length glycoprotein of about 300 amino acids, much larger than short synthetic research peptides [2, 4].
Is follistatin FDA approved?
No. As of October 2026 no follistatin product is approved by the FDA; gene-transfer forms have only been tested in early-phase studies [7].
Is follistatin on the WADA Prohibited List?
Yes. It is named in section S4 of the 2026 WADA Prohibited List as an example of a myostatin-binding protein [8].
Sources
- Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA. 1987;84(23):8282–8286. doi:10.1073/pnas.84.23.8282. Link
- Shimasaki S, Koga M, Esch F, et al. Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA. 1988;85(12):4218–4222. PMID 3380788. Link
- Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. Activin-binding protein from rat ovary is follistatin. Science. 1990;247(4944):836–838. doi:10.1126/science.2106159. Link
- Atlas of Genetics and Cytogenetics in Oncology and Haematology. FST (follistatin) gene entry: isoforms FST344/FST317, FS315/FS288, heparan sulfate binding. Link
- Mendell JR, Sahenk Z, Malik V, et al., Kaspar BK. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23(1):192–201. PMID 25322757. Link
- Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell. 2005;9(4):535–543. doi:10.1016/j.devcel.2005.09.008. Link
- ClinicalTrials.gov. NCT01519349: Follistatin gene transfer to patients with Becker muscular dystrophy and sporadic inclusion body myositis (Nationwide Children's Hospital; Phase 1; completed Oct 2017). Link
- World Anti-Doping Agency. 2026 Prohibited List, section S4 (myostatin-binding proteins, e.g. follistatin). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
